## Yakult

# Supplementary Materials for Financial Statements For the first quarter Ended June 30, 2012 (April 1, 2012 to June 30, 2012) 

July 27, 2012
Yakult Honsha Co., Ltd.
Public Relations Department
Investor Relations Department
URL http://ir.yakult.co.jp/

## Consolidated

1.Major Increases (Decreases) in Consolidated Balance Sheet $\cdot \boldsymbol{C} \cdot \boldsymbol{\cdot} \cdot 1$
2. Major Increases (Decreases) in Consolidated Statement of Income • 2

4. Segment Information $\cdot$....................................................... 4-6
5. Overseas companies Dairy Products sales( Bottles sold per day ) • : 7

## (Reference ) Information of Non-Consolidated

1.Breakdown of Statement of Income....................................... 8
2.Non-consolidated sales breakdown .................................. 8 -
3.Expansion of Indication for Pharmaceuticals . . . . . ...................... 11

About a numeric display of this material
1.Unit of money : Less than one million yen is rounded down.
2. Quantity results: Less than 1,000 is rounded off.
3. Year on year percentage: The second place is rounded off after the decimal point.

## Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet
(Millions of yen)

|  | $\begin{gathered} \text { As of Mar. } 31 \\ 2012 \end{gathered}$ | $\begin{gathered} \text { As of Jun. } 30 \\ 2012 \end{gathered}$ | Increase <br> (Decrease) |
| :---: | :---: | :---: | :---: |
| Total Assets | 397,213 | 416,572 | 19,358 |
| Current assets |  |  |  |
| Cash and deposits | 79,119 | 90,110 | 10,990 |
| Notes and accounts receivable | 52,531 | 55,000 | 2,468 |
| Inventories | 31,204 | 30,881 | (323) |
| Others | 14,737 | 16,154 | 1,416 |
| Fixed assets |  |  |  |
| Tangible fixed assets |  |  |  |
| Buildings and structures | 47,979 | 47,808 | (170) |
| Others | 88,983 | 91,442 | 2,458 |
| Intangible fixed assets | 5,903 | 5,850 | (53) |
| Investments and other assets |  |  |  |
| Investment securities | 65,279 | 67,461 | 2,182 |
| Others | 11,473 | 11,863 | 389 |
| Total Liabilities | 144,970 | 153,839 | 8,868 |
| Current liabilities |  |  |  |
| Notes and accounts payable | 24,638 | 27,220 | 2,582 |
| Short-term loans | 5,118 | 15,843 | 10,725 |
| Allowance for loss on plants reorganization | 1,530 | 2,168 | 638 |
| Others | 40,695 | 36,943 | $(3,751)$ |
| Fixed liabilities |  |  |  |
| Long-term loans | 42,342 | 42,219 | (122) |
| Allowance for retirement benefits | 17,863 | 17,784 | (78) |
| Allowance for loss on plants reorganization | 638 | - | (638) |
| Asset retirement obligation | 807 | 800 | (6) |
| Others | 11,338 | 10,859 | (479) |
| Total Net Assets | 252,242 | 262,732 | 10,489 |
| Shareholder's Equity | 274,247 | 273,485 | (761) |
| Accumulated other comprehensive income | $(45,621)$ | $(37,657)$ | 7,963 |
| Minority Interests | 23,616 | 26,904 | 3,287 |

2. Major Increases (Decreases) in Consolidated Statement of Income


## 3. Performance Overview

(1) Breakdown of Statement of Income
(Millions of yen)

|  | $\begin{gathered} \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | $\begin{gathered} \text { 1Q of FY } 2013 \\ \text { (April 1, } 2012 \sim \text { June 30, 2012) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Net sales | 76,014 | 101.9 | 77,690 | 102.2 |
| Operating income | 4,833 | 85.4 | 2,903 | 60.1 |
| Ordinary income | 6,439 | 92.3 | 4,645 | 72.1 |
| Net income | 2,162 | 68.3 | 1,008 | 46.6 |

(2) Breakdown of Gains on Equity Method
(Millions of yen)

|  | $\begin{gathered} \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | $\begin{gathered} \text { 1Q of FY } 2013 \\ \text { (April 1, } 2012 \sim \text { June 30, 2012) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Investment gains on the equity method |  | 78.0 | 1,144 | 186.2 |

## 4.Segment Information

## (1) Actual Results

(1)Result of first quarter ended June 30, 2011 (April 1, 2011 ~ June 30, 2011)
(Millions of yen)

|  | Food and beverages |  |  |  |  |  |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | :---: | :---: | :---: | :---: | :---: |
|  | Japan |  |  |  |  |  | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 47,706 | 18,428 | 9,908 | 6,322 | 2,196 |  |  |  |  |  |
| Percentage of net sales (\%) | 62.8 | 24.2 | 13.0 | 8.3 | 2.9 |  |  |  |  |  |
| Year on year (\%) | 101.1 | 109.7 | 107.5 | 122.1 | 91.5 |  |  |  |  |  |
| Operating expenses | 44,926 | 14,872 | 7,430 | 5,291 | 2,150 |  |  |  |  |  |
| Year on year (\%) | 100.4 | 110.7 | 108.0 | 119.4 | 101.5 |  |  |  |  |  |
| Operating income (loss) | 2,780 | 3,555 | 2,478 | 1,031 | 46 |  |  |  |  |  |
| Year on year (\%) | 114.7 | 105.7 | 106.2 | 138.2 | 16.3 |  |  |  |  |  |
| Operating income <br> margin (\%) | 5.8 | 19.3 | 25.0 | 16.3 | 2.1 |  |  |  |  |  |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 9,695 | 3,721 | 79,551 | $(3,536)$ | 76,014 |
| Percentage of net sales (\%) | 12.8 | 4.9 | 104.7 | $(4.7)$ | 100.0 |
| Year on year (\%) | 98.4 | 103.1 | 102.7 | 125.0 | 101.9 |
| Operating expenses | 7,432 | 3,962 | 71,193 | $(12)$ | 71,181 |
| Year on year (\%) | 114.6 | 103.1 | 103.9 | --- | 103.2 |
| Operating income (loss) | 2,263 | $(241)$ | 8,357 | ※ | $(3,524)$ |
| Year on year (\%) | 67.3 | --- | 93.8 | 108.3 | 4,833 |
| Operating income <br> margin (\%) | 23.3 | --- | --- | --- | 85.4 |

※Adjustment $\cdots 3,524$ million yen of adjustment include 3,144 million yen of administrative expenses in parent company.
Also note that the amount of difference for 379 million yen is elimination of royalty income.
(2)Result of first quarter ended June 30, 2012 (April 1, 2012 ~ June 30, 2012)

|  | Food and beverages |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 48,362 | 20,260 | 9,933 | 8,238 | 2,089 |
| Percentage of net sales (\%) | 62.3 | 26.1 | 12.8 | 10.6 | 2.7 |
| Year on year (\%) | 101.4 | 109.9 | 100.2 | 130.3 | 95.1 |
| Operating expenses | 47,214 | 16,274 | 7,648 | 6,550 | 2,074 |
| Year on year (\%) | 105.1 | 109.4 | 102.9 | 123.8 | 96.5 |
| Operating income (loss) | 1,147 | 3,986 | 2,284 | 1,687 | 14 |
| Year on year (\%) | 41.3 | 112.1 | 92.2 | 163.6 | 31.4 |
| Operating income margin (\%) | 2.4 | 19.7 | 23.0 | 20.5 | 0.7 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,643 | 3,888 | 81,154 | $(3,464)$ | 77,690 |
| Percentage of net sales (\%) | 11.1 | 5.0 | 104.5 | (4.5) | 100.0 |
| Year on year (\%) | 89.2 | 104.5 | 102.0 | 98.0 | 102.2 |
| Operating expenses | 7,274 | 3,799 | 74,561 | 225 | 74,787 |
| Year on year (\%) | 97.9 | 95.9 | 104.7 | --- | 105.1 |
| Operating income (loss) | 1,369 | 89 | 6,593 | * (3,689) | 2,903 |
| Year on year (\%) | 60.5 | --- | 78.9 | 104.7 | 60.1 |
| Operating income margin (\%) | 15.8 | 2.3 | --- | --- | 3.7 |

※Adjustment $\cdots 3,689$ million yen of adjustment include 3,199 million yen of administrative expenses in parent company.
Also note that the amount of difference for 490 million yen is elimination of royalty income.

## 〈Reference〉

Result of first quarter ended June 30, 2012 (using exchange rate of the average 2011.(Jan. -Mar. 2011))
Result of first quarter ended June 30, 2012(estimate)
(Millions of yen)

|  | Food and beverages |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan |  | Overseas Total | The Americas | Asia and Oceania |
| Net sales | 48,362 | 21,465 | 10,874 | 8,375 | 2,215 |
| Percentage of net sales (\%) | 61.3 | 27.2 | 13.8 | 10.6 | 2.8 |
| Year on year (\%) | 101.4 | 116.5 | 109.7 | 132.5 | 100.9 |
| Operating expenses | 47,214 | 17,262 | 8,357 | 6,696 | 2,209 |
| Year on year (\%) | 105.1 | 116.1 | 112.5 | 126.6 | 102.7 |
| Operating income (loss) | 1,147 | 4,202 | 2,517 | 1,678 | 6 |
| Year on year (\%) | 41.3 | 118.2 | 101.6 | 162.7 | 14.1 |
| Operating income <br> margin (\%) | 2.4 | 19.6 | 23.1 | 20.0 | 0.3 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 8,643 | 3,888 | 82,359 | $(3,464)$ | 78,894 |
| Percentage of net sales (\%) | 11.0 | 4.9 | 104.4 | $(4.4)$ | 100.0 |
| Year on year (\%) | 89.2 | 104.5 | 103.5 | 98.0 | 103.8 |
| Operating expenses | 7,274 | 3,799 | 75,550 | 225 | 75,775 |
| Year on year (\%) | 97.9 | 95.9 | 106.1 | --- | 106.5 |
| Operating income (loss) | 1,369 | 89 | 6,808 | ※ | $(3,689)$ |
| Year on year (\%) | 60.5 | --- | 81.5 | 104.7 | 3,119 |
| Operating income <br> margin (\%) | 15.8 | 2.3 | --- | --- | 64.5 |

※Adjustment $\cdot \cdots 3,689$ million yen of adjustment include 3,199 million yen of administrative expenses in parent company.
Also note that the amount of difference for 490 million yen is elimination of royalty income.

## 5. Overseas companies Dairy Products sales( Bottles sold per day )

(Unit:Thousands of bottles/day. \%)

|  | Consolidation Classification | 1Q of FY 2013(From January to March, 2012) |  | Preliminary figure <br> (From January to June, 2012) |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales quantity | Year on year (\%) | Sales quantity | Year on year (\%) |
| Taiwan | Equity method | 677 | 119.4 | 861 | 110.8 |
| Hong Kong | Consolidated | 454 | 125.0 | 504 | 116.1 |
| Thailand $\quad$ \% 1 | Equity method | 2,581 | 96.2 | 2,275 | 85.6 |
| Korea | Equity method | 3,673 | 99.5 | 4,176 | 103.9 |
| Philippines | Equity method | 1,492 | 127.1 | 1,490 | 125.2 |
| Singapore | Consolidated | 200 | 106.6 | 212 | 108.7 |
| Indonesia | Consolidated | 2,311 | 113.7 | 2,551 | 116.6 |
| Australia | Consolidated | 217 | 109.2 | 217 | 106.3 |
| Malaysia | Consolidated | 214 | 121.3 | 227 | 122.6 |
| Vietnam | Consolidated | 84 | 168.5 | 98 | 177.1 |
| India $\quad$ ※2 | Consolidated | 62 | 168.6 | 67 | 167.7 |
| Guangzhou | Consolidated | 1,079 | 129.6 | 1,275 | 118.0 |
| Shanghai | Consolidated | 259 | 130.7 | 337 | 132.4 |
| Beijing | Consolidated | 178 | 124.9 | 196 | 126.3 |
| China $\quad$ \% | Consolidated | 602 | 150.8 | 748 | 153.7 |
| China total |  | 2,118 | 134.7 | 2,556 | 129.3 |
| Asia and Oceania total <br> (Consolidated subsidiaries company Total) |  | $\begin{array}{r} 14,083 \\ 5,660 \end{array}$ | $\begin{aligned} & 110.6 \\ & 122.6 \end{aligned}$ | $\begin{array}{r} 15,235 \\ 6,433 \end{array}$ | $\begin{aligned} & 109.4 \\ & 121.9 \end{aligned}$ |
| Brazil | Consolidated | 1,857 | 108.4 | 1,805 | 106.9 |
| Mexico | Consolidated | 3,259 | 98.7 | 3,337 | 98.3 |
| Argentina | Consolidated | 17 | 88.6 | 15 | 75.7 |
| USA | Consolidated | 142 | 123.8 | 152 | 129.3 |
| The Americas total |  | 5,275 | 102.4 | 5,310 | 101.7 |
| Netherlands | Consolidated | 230 | 97.3 | 222 | 98.3 |
| Belgium | Consolidated | 75 | 92.9 | 71 | 88.5 |
| United Kingdom | Consolidated | 236 | 104.0 | 231 | 107.8 |
| Germany | Consolidated | 104 | 83.6 | 94 | 82.8 |
| Austria | Consolidated | 20 | 114.8 | 18 | 94.9 |
| Italy $\quad$ \% | Consolidated | 81 | 145.8 | 82 | 140.1 |
| Europe total |  | 746 | 100.6 | 720 | 100.9 |
| Total <br> (Consolidated subsidiaries | pany Total) | $20,103$ <br> 11,681 | $108.0$ $111.2$ | 21,265 <br> 12,463 | $\begin{aligned} & 107.1 \\ & 111.1 \end{aligned}$ |

<Accounting period: From January to December>
$※ 1$ :Thailand : Accounting date:31 May.
※2:India: Accounting date: 31 Mar. Hyderabad (Started sales from 19 February. 2012) Chennai (Started sales from 5 April. 2012)
$※ 3$ : (1)Sales Area of Yakult (China) : Nanjing city, Tianjin city, Suzhou city, Hangzhou city, Qingdao city, Ningbo city, Jinan city, Wuhan city, Wenzhou city, Yantai city, Shenyang city, Xiamen city, Dalian city, Fuzhou city, Hefei city, Xi'an city(Started sales from 27 February. 2012) Changsha city(Started sales from 1 March. 2012) Shijiazhuang city(Started sales from 2 April. 2012), Nanchang city(Started sales from 2 April. 2012) Changchun city(Started sales from 2 July,2012) and neighboring cities. (excluding Guangdong, Hainan, Shanghai city and Beijing city) Started home delivery sales in Tianjin city from 26 March. 2012.
(2)Tianjin Yakult : Delivers products to Yakult (China) (Started manufacturing from 3 Aug. 2011)
※4:Italy:Yakult Light(Started sales from 1 April. 2012)

## (Reference)

Non-Consolidated

Non-consolidated financial results are presented in accordance with "Regulation for quarterly financial statements".
But, it is not subject to be reviewed by auditors under the law.

## 1. Breakdown of Statements of Income

(Millions of yen)

|  | $\begin{gathered} \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | $\begin{gathered} \text { 1Q of FY } 2013 \\ \text { (April 1, } 2012 \sim \text { June 30, 2012) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Net sales | 44,496 | 99.3 | 43,705 | 98.2 |
| Operating income | 994 | 36.3 | $(1,085)$ | --- |
| Ordinary income | 2,661 | 65.4 | 450 | 16.9 |
| Net income | 322 | 12.4 | $(1,312)$ | --- |

## 2. Sales breakdown

(1) Sales by Product Category
(Millions of yen)

|  | $\begin{gathered} \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | $\begin{gathered} \text { 1Q of FY } 2013 \\ \text { (April 1, } 2012 \sim \text { June 30, 2012) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Dairy Products | 18,927 | 92.8 | 20,086 | 106.1 |
| Juices and Other Beverages | 9,932 | 105.0 | 9,673 | 97.4 |
| Subtotal | 28,859 | 96.7 | 29,759 | 103.1 |
| Cosmetics | 1,598 | 101.9 | 1,599 | 100.1 |
| Pharmaceuticals | 9,695 | 98.4 | 8,643 | 89.2 |
| Others | 4,342 | 122.0 | 3,702 | 85.3 |
| Total | 44,496 | 99.3 | 43,705 | 98.2 |

( 2 ) Dairy Products sales (Bottles sold per day)
(Thousands of bottles/day)

|  |  | $\begin{array}{r} 1 Q \text { of } \mathrm{F} \text { ) } \\ \text { (April 1, } 2011 \sim \end{array}$ | $\begin{aligned} & \text { Y } 2012 \\ & \text { June 30, 2011) } \end{aligned}$ | $\begin{array}{r} 1 Q \text { of } \mathrm{F} \\ \text { (April 1, } 2012 \sim \end{array}$ | $\text { Y } 2013$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Results | Year on year(\%) | Results | Year on year(\%) |
|  | Yakult | 3,336 | 102.0 | 3,232 | 96.9 |
|  | Yakult Calorie Half ※2 | 12 | 8.4 | 172 | 1387.0 |
|  | Yakult 300V ※2 | 11 | 6.8 | 115 | 1085.4 |
|  | Yakult SHEs $\quad$ (2 | 6 | 7.9 | 42 | 729.3 |
|  | Total for Yakult 400 products | 3,129 | 101.8 | 3,233 | 103.3 |
|  | Yakult 400 | 1,250 | 89.8 | 1,132 | 90.6 |
|  | Yakult 400LT | 1,880 | 111.7 | 2,100 | 111.8 |
|  | Total for Yakult products | 6,494 | 96.3 | 6,794 | 104.6 |
|  | BF-1 | 108 | 96.2 | 93 | 85.6 |
|  | Pretio | 135 | 86.9 | 220 | 163.7 |
|  | Joie | 759 | 104.5 | 764 | 100.7 |
|  | Mil-Mil | 613 | 133.0 | 527 | 86.0 |
|  | Sofuhl $\quad$ \%1 | 355 | 66.7 | 522 | 147.1 |
|  | Purela | 215 | 136.0 | 169 | 78.4 |
|  | Yakult Genki Yogurt ※2* | 2 | --- | 9 | 526.1 |
|  | Total for fermented milk | 1,943 | 90.5 | 1,991 | 102.5 |
|  | Total | 8,680 | 94.8 | 9,098 | 104.8 |

※1 Sofuhl Genki Yogurt (Launched on June 4, 2012) is included.
※2 Sales stopped until late June 2011 due to the Great East Japan Earthquake.

* Sales stopped
( 3 ) Juices and Other Beverages sales (Total Bottles sold)

|  |  | (Thousands of bottles) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\begin{gathered} \hline \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | 1Q of FY 2013(April 1, 2012 ~ June 30, 2012) |  |
|  |  | Results | Year on year(\%) | Results | Year on year(\%) |
|  | Bansoreicha | 9,074 | 90.1 | 7,786 | 85.8 |
|  | Toughman | 23,376 | 164.7 | 20,453 | 87.5 |
|  | Kurozu Drink | 12,174 | 86.3 | 10,507 | 86.3 |
|  | Soy milk drinks | 10,992 | 107.1 | 12,264 | 111.6 |
| E | Lemorea | 2,385 | 71.0 | 2,049 | 85.9 |
|  | Milouge | 10,523 | 135.4 | 11,172 | 106.2 |
|  | Juices | 17,683 | 107.7 | 16,216 | 91.7 |
|  | Kininaruyasai | 16,545 | 111.9 | 15,234 | 92.1 |
| 告 | Coffee Time | 9,434 | 98.9 | 7,774 | 82.4 |
| 若 | FIRE | 20,089 | 103.9 | 18,247 | 90.8 |
|  | Coffee products total | 29,523 | 102.2 | 26,021 | 88.1 |
|  | Gogono-kocha | 9,310 | 126.5 | 7,626 | 81.9 |

(4) Pharmaceuticals sales
(Millions of yen)

|  | $\begin{gathered} \hline \text { 1Q of FY } 2012 \\ \text { (April 1, } 2011 \sim \text { June 30, 2011) } \end{gathered}$ |  | $\begin{gathered} \text { 1Q of FY } 2013 \\ \text { (April 1, } 2012 \sim \text { June 30, 2012) } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Results | Year on year(\%) | Results | Year on year(\%) |
| Campto (Japan) | 702 | 89.5 | 566 | 80.7 |
| Campto (Overseas) | 528 | 222.2 | 356 | 67.6 |
| The Americas | --- | --- | --- | --- |
| Europe | 528 | 350.6 | 153 | 29.2 |
| Other | --- | --- | 203 | --- |
| Campto total | 1,230 | 120.3 | 923 | 75.0 |
| Elplat | 7,228 | 94.9 | 6,173 | 85.4 |
| Other pharmaceuticals | 1,237 | 102.1 | 1,547 | 125.1 |
| Total | 9,695 | 98.4 | 8,643 | 89.2 |

## 3. Expansion of Indication for Pharmaceuticals

## Elplat phase II study initiation for gastric cancer adjuvant therapy

We have been conducting a phase III study (SOX regimen vs S-1 alone ) to file sNDA for the treatment of $1^{\text {st }}$ line on advanced/recurrent gastric caner. We plan to submit the sNDA in coming December.
As for the adjuvant therapy, we and Chugai Seiyaku jointly commenced a phase II study by XELOX regimen in July to seek for the sNDA.
For the reference, the study information is available on URL of JAPIC Clinical Trials Information.

## CAUTIONARY STATEMENT

Statements contained in these materials with respect to Yakult's plans, forecasts and other statements that are not historical facts are forwardlooking statements that involve risks and uncertainties that could cause actual results to differ substantially from expectations.
The information contained in these materials is not intended as a solicitation for investment. Furthermore, Yakult does not guarantee the accuracy of the contents of these materials. Yakult and the provider of these materials disclaim any responsibility for any loss or damage that should arise from the use of this information.

